title: Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.
abstract: BACKGROUND
  The usefulness of serum proteomic test (VeriStrat) in African-Americans with non-small cell lung cancer (NSCLC) as well as the relationship between comorbidity and test performance have not been studied.
  
  
  METHODS
  We reviewed records of patients with NSCLC in our practice for whom VeriStrat was performed to assist with the selection of therapy. We correlated survival with VeriStrat test classification, race, and comorbidity index using SAS software 9.4.
  
  
  RESULTS
  We identified 49 qualified patients; 33 with VeriStrat Good (VSG), 16 with VeriStrat Poor (VSP). When stratified by VSG vs. VSP, overall survival (OS) did not differ between African-Americans and Whites [hazard ratio (HR)test (VSG/VSP)=0.78, 95% confidence interval (CI)=0.38-1.61; p=0.51]. OS adjusted for mean Charlson Comorbidity Index (CCI) was not different between erlotinib- and chemotherapy-treated groups in patients with non-squamous NSCLC (adjusted HR=0.91, 95% CI= 0.37-2.23; p=0.84), but was inferior in patients with squamous NSCLC treated with erlotinib (adjusted HR=10.6, 95% CI=1.28-87.8; p=0.029). Cox proportional hazard model for OS effect of VeriStrat test was estimated after adjusting for CCI. In both the VSG and VSP groups, a higher CCI value was associated with lower survival, and at any CCI value, the VSG group had better survival than the VSP group.
  
  
  CONCLUSIONS
  Our study corroborates that race does not influence prognostic and predictive values of VeriStrat; however, comorbidities have a significant impact on survival in each proteomic stratum.
authors.affiliation: School of Public Health, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
authors.forename: Mani
authors.initials: M
authors.lastname: Keshtgarpour
authors.affiliation: School of Public Health, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
authors.forename: Wei Seong
authors.initials: WS
authors.lastname: Tan
authors.affiliation: School of Public Health, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
authors.forename: Jack
authors.initials: J
authors.lastname: Zwanziger
authors.affiliation: School of Public Health, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
authors.forename: Saria
authors.initials: S
authors.lastname: Awadalla
authors.affiliation: School of Public Health, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A.
authors.forename: Fredrick G
authors.initials: FG
authors.lastname: Langi
authors.affiliation: Division of Hematology/Oncology, College of Medicine, University of Illinois at Chicago, Chicago, IL, U.S.A. adudek@uic.edu.
authors.forename: Arkadiusz Z
authors.initials: AZ
authors.lastname: Dudek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015897:Comorbidity; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics / Q000379:methods; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D020543:Proteome; D000069347:Erlotinib Hydrochloride
keywords: African-American; Lung cancer; VeriStrat; proteomic mass spectrometry; race